Leger Tina Amber St Sells 1,000 Shares of Immunocore (NASDAQ:IMCR) Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) insider Leger Tina Amber St sold 1,000 shares of Immunocore stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company’s stock, valued at $36,199.65. This represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunocore Stock Performance

Immunocore stock traded up $0.66 during midday trading on Thursday, reaching $33.17. 392,220 shares of the company traded hands, compared to its average volume of 465,558. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $40.71. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. The business has a 50 day moving average of $33.94 and a two-hundred day moving average of $34.31. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -58.19 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. UBS Group set a $55.00 price objective on Immunocore and gave the stock a “buy” rating in a report on Wednesday, January 7th. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, January 22nd. Finally, Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.90.

Key Stories Impacting Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Immunocore will report fourth-quarter and full-year 2025 results and host an earnings call on Feb. 25 — a near-term catalyst that can drive volatility and provide fresh guidance. GlobeNewswire: Earnings Release
• Neutral Sentiment: Short-interest data in the February snapshot shows zero shares short and a 0.0 days-to-cover figure — this appears anomalous and is likely a reporting error, so it should not be treated as a clear bullish signal.
• Negative Sentiment: CEO Bahija Jallal sold 11,474 shares at an average price of $32.35 (about $371k), cutting her holding roughly in half — a sizable insider sell that can weigh on sentiment. SEC Filing — CEO Sale
• Negative Sentiment: CFO/CAO John Goll sold 698 shares at $32.35, reducing his stake by ~52% — another insider reduction that may prompt investor questions about timing. SEC Filing — CAO Sale
• Negative Sentiment: Senior exec David M. Berman sold 5,965 shares at $32.35 (~$193k), cutting his position by about half — contributes to the cluster of insider selling. SEC Filing — Insider Sale
• Negative Sentiment: Leger Tina Amber St sold 1,000 shares at $32.35, also materially reducing her stake — another data point of concentrated insider selling on Feb. 18. SEC Filing — Insider Sale

Institutional Investors Weigh In On Immunocore

Several institutional investors and hedge funds have recently modified their holdings of IMCR. Primecap Management Co. CA lifted its holdings in shares of Immunocore by 5.5% in the fourth quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company’s stock worth $137,517,000 after buying an additional 207,320 shares in the last quarter. Bellevue Group AG increased its holdings in Immunocore by 14.5% in the 3rd quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after acquiring an additional 354,973 shares during the last quarter. Tang Capital Management LLC lifted its stake in Immunocore by 14.0% in the 4th quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock worth $91,237,000 after purchasing an additional 322,930 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Immunocore by 334.3% during the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after purchasing an additional 974,463 shares during the last quarter. Finally, Armistice Capital LLC boosted its holdings in shares of Immunocore by 33.3% during the 4th quarter. Armistice Capital LLC now owns 1,098,000 shares of the company’s stock valued at $38,112,000 after purchasing an additional 274,000 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.